Mar. 18 at 5:59 PM
$SCYX
SCY-247 has a compelling profile for acquisition after a Phase 2 success. Phase 1 showed clean safety and good drug exposure. The FDA granted both Fast Track and QIDP designations, signaling genuine unmet need recognition. It improves on ibrexafungerp with better bioavailability, IV/oral flexibility, and higher preclinical fungicidal activity.
The acquisition logic is strong — antifungal drug classes are few, resistance to azoles and echinocandins is accelerating, and Candida auris is spreading globally.
Any large pharma with an infectious disease franchise would view a positive Phase 2 as a low-risk bolt-on. QIDP’s 10-year market exclusivity guarantee makes the economics attractive to an acquirer.
The likely sweet spot is a deal after Phase 2 data (potentially late 2026 or early 2027) but before Phase 3 begins — when SCYX captures real value but the acquirer still owns the commercial story.
This is a legitimate moonshot with better-than-average odds.
